Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Panagen
- Development stage
- Phase 2
- Lead developer
- HLB PANAGENE
- Modality
- Small Molecules, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Oral
01
Overview
Panagen is a placental-derived fragmented double-stranded human DNA therapy developed for the treatment of breast cancer. The drug acts as an immunostimulant by activating dendritic cells and inducing the development of an adaptive anticancer immune response. In clinical studies, Panagen demonstrated leukostimulatory and leukoprotective effects when combined with chemotherapy, helping to maintain innate antitumor immunity and increase cytotoxic CD8+ T-cell formation. It is administered orally in tablet form during chemotherapy regimens[1][3][4].
- Brand names
- Panagen
- Other names
- double-stranded human DNAfragmented DNAplacental DNAsodium deoxyribonucleate
02
Targets
TLR9 (Toll-like receptor 9)
Beyond the preview
Go deeper on Panagen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Panagen.